Erasca Q2 2026: $44.1M Net Loss, $384M Cash, and ERAS-0015 Data Fuel Registration Plans

summarizeSummary

Erasca posted a $44.1 million Q2 net loss and held $384 million in cash, while updated ERAS-0015 data in pancreatic cancer backs plans for three registration-enabling trials. A $632 million July offering further strengthens the balance sheet ahead of important data readouts.

check_boxKey Events · Earnings and Guidance · ERAS

• Q2 2026 Financial Results

  Net loss widened to $44.1 million ($0.14/share) from $33.9 million a year ago, as R&D expenses climbed to $35.9 million on higher clinical trial costs. Cash, equivalents, and marketable securities totaled $384.3 million as of June 30, 2026.

• ERAS-0015 Updated Clinical Data

  At the 32 mg dose, ERAS-0015 achieved a 57% unconfirmed overall response rate at 8 weeks in second-line+ KRAS G12X pancreatic cancer, with favorable tolerability and no dose-limiting toxicities. The panitumumab combination also cleared its first dose escalation cohort.

• Registration-Enabling Plans

  Three potentially registration-enabling trials are planned for ERAS-0015: a Phase 3 in first-line PDAC, a Phase 3 in RAS-mutant NSCLC, and a trial in second-line+ NSCLC, with initiations expected from H1 2027 to H1 2028.

• Upcoming Catalysts

  Phase 1 monotherapy expansion and combination data for ERAS-0015 are expected in H1 2027, while preliminary monotherapy data for ERAS-4001 (pan-KRAS inhibitor) are anticipated in H2 2026.

auto_awesomeAnalysis · ERAS · Life Sciences

Erasca's Q2 update pairs financial results with fresh clinical data for its lead asset, ERAS-0015, which delivered a 57% unconfirmed response rate in pancreatic cancer and supports three registration-enabling trials. The $384 million cash position (pre-July offering) and a $632 million July raise provide the runway needed to execute these pivotal studies. With the stock under pressure from a patent dispute and class action lawsuit, this clinical and financial update serves as a key sentiment check.